PASSAGE BIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
PASSAGE BIO, INC. (PASG) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.10% for the 12-month period ending 2025-12-31, per its S-4/A filed 2026-09-03.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-09-03
- PASSAGE BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-03-31 was 3.50%, a 133.33% increase year-over-year.
- PASSAGE BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2022-03-31 was 1.50%, a 87.50% increase year-over-year.
- PASSAGE BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2021-03-31 was 0.80%, a 42.86% decline year-over-year.
- PASSAGE BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2020-03-31 was 1.40%, a 44.00% decline year-over-year.
- PASSAGE BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 3.60%, a 28.57% increase from fiscal 2022.
- PASSAGE BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 2.80%, a 211.11% increase from fiscal 2021.
- PASSAGE BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2021 was 0.90%, a 25.00% decline from fiscal 2020.
- PASSAGE BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2020 was 1.20%, a 40.00% decline from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2025-12-31 | 4.10% S-4/A · filed 2026-09-03 | |||
| 2024-12-31 | 4.20% S-4/A · filed 2026-09-03 | |||
| 2023-12-31 | 3.60% 10-K · filed 2025-03-04 | |||
| 2023-06-30 | 3.60% 10-Q · filed 2023-08-07 | |||
| 2023-03-31 | 3.50% 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | 2.80% 10-K · filed 2024-03-04 | |||
| 2022-09-30 | 2.60% 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | 2.60% 10-Q · filed 2023-08-07 | |||
| 2022-03-31 | 1.50% 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | 0.90% 10-K · filed 2023-03-06 | |||
| 2021-09-30 | 0.90% 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | 0.90% 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | 0.80% 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | 1.20% 10-K · filed 2022-03-03 | |||
| 2020-09-30 | 1.20% 10-Q · filed 2021-11-04 | |||
| 2020-06-30 | 1.30% 10-Q · filed 2021-08-05 | |||
| 2020-03-31 | 1.40% 10-Q · filed 2021-05-05 | |||
| 2019-12-31 | 2.00% 10-K · filed 2021-03-03 | |||
| 2019-09-30 | 2.40% 10-Q · filed 2020-11-10 | |||
| 2019-06-30 | 2.40% 10-Q · filed 2020-08-13 | |||
| 2019-03-31 | 2.50% 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |